Edgar Filing: MusclePharm Corp - Form 4

Form 4											
FORM Check this b if no longer subject to Section 16. Form 4 or Form 5 obligations may continu	subject to Section 16. Form 4 or Form 5 obligations may continue. See InstructionSTATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESSection 16. Form 5 obligations may continue. See InstructionSection 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5			
(Print or Type Res	sponses)										
BLUHER JOHN H Symbol			and there is the first of the f				5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) (Middle) 3. Date o			of Earliest Transaction Day/Year) 2012				(Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) EVP - COO				
				nth/Day/Year) A				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
DENVER, CC) US 80239							_ Form filed by Mo erson			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative Secu	irities	Acquir	ed, Disposed of,	or Beneficiall	y Owned	
	Transaction Date Ionth/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	4. Securities A nor Disposed of (Instr. 3, 4 and Amount	(D)	d (A) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common 11 Stock 11	1/16/2012			A <u>(1)</u>	60,000,000	A	<u>(2)</u>	76,650,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: MusclePharm Corp - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
BLUHER JOHN H 4721 IRONTON STREET, BUILDING A DENVER, CO US 80239	A X		EVP - COO					
Signatures								
/s/ John H. 11/20/2012 Bluher								

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This restricted stock unit award vests in three equal annual installments on January 1, 2013, January 1, 2014 and December 1, 2014, subject to continued employment of the reporting person with the Registrant.
- (2) Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.